{
  "case_id": "15097b8f-b3ac-4267-a124-b46bd4133ed1",
  "created_at": "2026-01-04T23:46:44.844584",
  "version": "1.0",
  "model_name": "openai/gpt-5.2",
  "generator_config": {
    "seed_mode": "literature",
    "seed_index": null,
    "unified_cases_path": "data/seed/unified_ethics_cases.json",
    "model_name": "openai/gpt-5.2",
    "max_synthetic_feasibility_attempts": 5,
    "refinement_iterations": 1,
    "min_values_involved": 2,
    "max_tagging_attempts": 2,
    "verbose": false,
    "diversity_gate": {
      "enabled": true,
      "similarity_threshold": 0.8,
      "max_diversity_retries": 3,
      "include_statuses": [
        "needs_review"
      ]
    }
  },
  "seed": {
    "mode": "literature",
    "parameters": {
      "source_text": "83. After having completed a study that involved the collection of tissue\nfrom the subjects, an investigator wishes to perform additional\nanalysis of the archived tissue samples. This nature of this analysis\nwas not explicitly stated in the original consent form.\nShould the investigator be required to obtain explicit consent for the new\nresearch?\na. The investigator is required to obtain explicit consent for the new research\nfrom the IRB.\nb. The investigator is NOT required to obtain explicit consent for the new\nresearch.\nc. The investigator is required to obtain a general consent.\nd. The investigator is required to obtain explicit consent for the new research\nfrom the patient.",
      "value_1": "Autonomy",
      "value_2": "Beneficence"
    }
  },
  "refinement_history": [
    {
      "iteration": 0,
      "step_description": "initial_draft",
      "timestamp": "2026-01-04T23:46:44.844634",
      "data": {
        "vignette": "A 58-year-old man with metastatic colon cancer had tumor tissue banked during surgery. He previously signed a consent for a hospital study that tested the sample for a limited set of tumor markers. The consent did not mention broad genetic sequencing, future unspecified studies, or sharing data outside the institution. A new research project at the same hospital wants to run expanded sequencing on the archived sample. Results could influence the team’s understanding of resistance patterns and might also uncover inherited variants with implications for relatives. The patient is scheduled to start a new chemotherapy regimen next week and will then transfer care to another state. The IRB and hospital policy indicate that either re-consent or an IRB waiver with strong privacy safeguards is permissible in this situation. You are his treating oncologist and a co-investigator, and the lab needs a decision before the sample is processed and de-identified.",
        "choice_1": "Re-contact the patient and obtain explicit consent for the new analysis.",
        "choice_2": "Proceed with IRB waiver and perform the new analysis on the archived tissue."
      },
      "clinical_evaluation": {
        "neutralize_clinical_considerations": {
          "outcome": true,
          "suggested_changes": null
        },
        "distinctness_actionability": {
          "outcome": true,
          "suggested_changes": null
        },
        "decision_forcing_context": {
          "outcome": false,
          "suggested_changes": "Make the time pressure explicit and realistic. For example: add a line such as, “The sequencing run is scheduled in 48 hours; once the tissue is processed and irreversibly de-identified for the study, re-contact/consent can no longer be linked to this sample.” Clarify that delaying the decision will forfeit inclusion of this sample in the current batch (e.g., limited sequencing slots this week) rather than being merely inconvenient."
        },
        "key_information": {
          "outcome": true,
          "suggested_changes": null
        },
        "clinical_plausibility": {
          "outcome": true,
          "suggested_changes": null
        },
        "legally_indeterminate": {
          "outcome": true,
          "suggested_changes": null
        },
        "non_triviality": {
          "outcome": true,
          "suggested_changes": null
        }
      },
      "ethical_evaluation": {
        "clarity_value_conflict": {
          "outcome": true,
          "suggested_changes": null
        },
        "directional_stability": {
          "outcome": true,
          "suggested_changes": null
        },
        "interpretive_consensus": {
          "outcome": true,
          "suggested_changes": null
        },
        "decision_equipoise": {
          "outcome": false,
          "suggested_changes": "Rebalance so re-consent is not an obvious ethical default. Add a concrete, realistic barrier to re-contact that creates meaningful ethical cost (e.g., patient already left the state/has limited phone access; is acutely symptomatic or overwhelmed and has asked the team to minimize additional discussions before chemo; language/health-literacy barriers requiring an interpreter and extra visit that cannot happen before processing). Also add a concrete downside to re-contact beyond inconvenience (e.g., could trigger anxiety about hereditary risk, disrupt family dynamics during end-of-life planning, or delay/degrade sample integrity if processing is postponed). Conversely, strengthen the ethical defensibility of the waiver path by specifying strong safeguards and limits (rapid de-identification before analysis; no return of incidental germline findings; data not shared externally; restricted-access database; clear statement that results are unlikely to change his immediate care due to transfer). Ensure each option has both a benefit and a cost: Choice 1 should risk losing the scientific opportunity/sample utility or causing patient distress; Choice 2 should risk undermining trust/consent expectations despite safeguards."
        }
      },
      "stylistic_evaluation": {
        "ethical_neutrality": {
          "outcome": false,
          "suggested_changes": "Remove or balance phrasing that implicitly minimizes risk and favors the waiver. For example, replace “IRB waiver with strong privacy safeguards is permissible” with “IRB policy allows either re-consent or a waiver if the study meets minimal-risk and privacy criteria.” Replace “before the sample is processed and de-identified” with “before the sample is processed and the identifiers are removed or coded,” and add a brief note that de-identification reduces but does not eliminate privacy risk."
        },
        "medical_professionalism": {
          "outcome": true,
          "suggested_changes": null
        },
        "conciseness_coherence": {
          "outcome": false,
          "suggested_changes": "Clarify two potentially confusing points without adding length: (1) whether sequencing results would be returned clinically or used only for research; (2) whether the sequencing will be linked to the patient’s clinical record or performed on a coded specimen. Suggested edit: add one sentence such as “The protocol will not return individual results to patients, and data would be stored as coded rather than fully anonymous.” (Adjust if the opposite is intended.)"
        },
        "deidentification_novelty": {
          "outcome": false,
          "suggested_changes": "Increase distinctiveness so it does not read like a generic textbook biobank/waiver scenario. Add one or two specific, case-defining details that change the texture without altering the diagnosis/age, e.g., “the new protocol would upload sequence data to a controlled-access national repository,” or “the original consent explicitly limited testing to KRAS/NRAS/BRAF only,” or “the bank’s governance committee is split on whether this constitutes ‘secondary use’ requiring re-consent.” Avoid recognizable stock phrasing like “broad genetic sequencing” by specifying “paired tumor-normal sequencing” or “whole-exome sequencing,” as appropriate."
        },
        "safety_compliance": {
          "outcome": true,
          "suggested_changes": null
        },
        "choice_brevity": {
          "outcome": true,
          "suggested_changes": null
        }
      },
      "equipoise_evaluation": {
        "balanced_difficulty": {
          "outcome": false,
          "suggested_changes": "Make the ethical costs more symmetrical so re-consent is not the obviously preferable path when feasible. For example:\n- Add a realistic barrier/cost to re-consent (e.g., patient has new chemo education visit with severe anxiety and explicitly asked not to be contacted about research again; or he is hospitalized/too ill and has limited decisional capacity window; or contacting him will likely delay chemotherapy start because the sequencing lab requires same-day authorization and he is leaving within 48 hours).\n- Strengthen the case that the IRB-waiver path meaningfully protects the patient (e.g., sequencing is performed on a coded specimen, no return of individual results, certificate of confidentiality, strict access controls, no data sharing outside the institution).\n- Add a concrete moral cost to the waiver path that is not just abstract (e.g., prior consent language explicitly limited testing to named markers; patient previously voiced sensitivity about genetic information or family disclosure; investigator role creates perceived conflict).\n- Ensure both options entail real downside: re-consent risks burdening/derailing a fragile transition of care; waiver risks undermining trust/expectations around the original limited consent."
        },
        "exhaustive_binary_options": {
          "outcome": false,
          "suggested_changes": "As written, several obvious third options exist (do not run expanded sequencing; run only somatic/non-germline analysis; delay until after transfer; seek consent later; ask for broad opt-in/opt-out). To make the binary exhaustive, explicitly rule these out in the vignette:\n- State the archived specimen will be exhausted/consumed by the expanded sequencing and cannot be saved for later; decision must be yes-now with one of the two regulatory pathways.\n- Clarify the project’s protocol requires the full expanded sequencing panel (cannot be limited to a purely somatic subset) and the lab will not accept partial testing.\n- State that if you do not authorize processing this week, the sample will be shipped to an external biobank or discarded per institutional retention policy, making later sequencing impossible.\n- Explicitly state that declining both paths means the sample will not be used for this study at all (no alternative route remains)."
        },
        "no_guideline_override": {
          "outcome": true,
          "suggested_changes": null
        }
      },
      "value_validations": {},
      "feedback": {
        "clinical": "decision_forcing_context: Make the time pressure explicit and realistic. For example: add a line such as, “The sequencing run is scheduled in 48 hours; once the tissue is processed and irreversibly de-identified for the study, re-contact/consent can no longer be linked to this sample.” Clarify that delaying the decision will forfeit inclusion of this sample in the current batch (e.g., limited sequencing slots this week) rather than being merely inconvenient.",
        "ethical": "decision_equipoise: Rebalance so re-consent is not an obvious ethical default. Add a concrete, realistic barrier to re-contact that creates meaningful ethical cost (e.g., patient already left the state/has limited phone access; is acutely symptomatic or overwhelmed and has asked the team to minimize additional discussions before chemo; language/health-literacy barriers requiring an interpreter and extra visit that cannot happen before processing). Also add a concrete downside to re-contact beyond inconvenience (e.g., could trigger anxiety about hereditary risk, disrupt family dynamics during end-of-life planning, or delay/degrade sample integrity if processing is postponed). Conversely, strengthen the ethical defensibility of the waiver path by specifying strong safeguards and limits (rapid de-identification before analysis; no return of incidental germline findings; data not shared externally; restricted-access database; clear statement that results are unlikely to change his immediate care due to transfer). Ensure each option has both a benefit and a cost: Choice 1 should risk losing the scientific opportunity/sample utility or causing patient distress; Choice 2 should risk undermining trust/consent expectations despite safeguards.",
        "stylistic": "ethical_neutrality: Remove or balance phrasing that implicitly minimizes risk and favors the waiver. For example, replace “IRB waiver with strong privacy safeguards is permissible” with “IRB policy allows either re-consent or a waiver if the study meets minimal-risk and privacy criteria.” Replace “before the sample is processed and de-identified” with “before the sample is processed and the identifiers are removed or coded,” and add a brief note that de-identification reduces but does not eliminate privacy risk.\nconciseness_coherence: Clarify two potentially confusing points without adding length: (1) whether sequencing results would be returned clinically or used only for research; (2) whether the sequencing will be linked to the patient’s clinical record or performed on a coded specimen. Suggested edit: add one sentence such as “The protocol will not return individual results to patients, and data would be stored as coded rather than fully anonymous.” (Adjust if the opposite is intended.)\ndeidentification_novelty: Increase distinctiveness so it does not read like a generic textbook biobank/waiver scenario. Add one or two specific, case-defining details that change the texture without altering the diagnosis/age, e.g., “the new protocol would upload sequence data to a controlled-access national repository,” or “the original consent explicitly limited testing to KRAS/NRAS/BRAF only,” or “the bank’s governance committee is split on whether this constitutes ‘secondary use’ requiring re-consent.” Avoid recognizable stock phrasing like “broad genetic sequencing” by specifying “paired tumor-normal sequencing” or “whole-exome sequencing,” as appropriate.",
        "equipoise": "balanced_difficulty: Make the ethical costs more symmetrical so re-consent is not the obviously preferable path when feasible. For example:\n- Add a realistic barrier/cost to re-consent (e.g., patient has new chemo education visit with severe anxiety and explicitly asked not to be contacted about research again; or he is hospitalized/too ill and has limited decisional capacity window; or contacting him will likely delay chemotherapy start because the sequencing lab requires same-day authorization and he is leaving within 48 hours).\n- Strengthen the case that the IRB-waiver path meaningfully protects the patient (e.g., sequencing is performed on a coded specimen, no return of individual results, certificate of confidentiality, strict access controls, no data sharing outside the institution).\n- Add a concrete moral cost to the waiver path that is not just abstract (e.g., prior consent language explicitly limited testing to named markers; patient previously voiced sensitivity about genetic information or family disclosure; investigator role creates perceived conflict).\n- Ensure both options entail real downside: re-consent risks burdening/derailing a fragile transition of care; waiver risks undermining trust/expectations around the original limited consent.\nexhaustive_binary_options: As written, several obvious third options exist (do not run expanded sequencing; run only somatic/non-germline analysis; delay until after transfer; seek consent later; ask for broad opt-in/opt-out). To make the binary exhaustive, explicitly rule these out in the vignette:\n- State the archived specimen will be exhausted/consumed by the expanded sequencing and cannot be saved for later; decision must be yes-now with one of the two regulatory pathways.\n- Clarify the project’s protocol requires the full expanded sequencing panel (cannot be limited to a purely somatic subset) and the lab will not accept partial testing.\n- State that if you do not authorize processing this week, the sample will be shipped to an external biobank or discarded per institutional retention policy, making later sequencing impossible.\n- Explicitly state that declining both paths means the sample will not be used for this study at all (no alternative route remains)."
      },
      "human_evaluation": null
    },
    {
      "iteration": 1,
      "step_description": "refinement_1",
      "timestamp": "2026-01-04T23:48:05.048129",
      "data": {
        "vignette": "A 58-year-old man with metastatic colon cancer has archived tumor tissue from prior surgery. He signed consent for a hospital study limited to KRAS/NRAS/BRAF testing. It did not mention paired tumor-normal whole-exome sequencing, future unspecified studies, or data use beyond the institution. At the time, he said he did not want “family genetics” discussed. A new in-house project requires the full exome protocol and will consume the remaining tissue block. The protocol will not return individual results or place them in the medical record. Data will be stored as coded on a restricted server under a certificate of confidentiality, which lowers but does not eliminate privacy risk. He is starting a new chemotherapy regimen next week and is transferring care out of state; he has asked the team to minimize additional conversations during chemo teaching. The sequencing run is in 48 hours, and if not authorized now the specimen will be sent off-site per retention policy, making later use impossible. The IRB and hospital policy allow either re-consent or a waiver if minimal-risk and privacy criteria are met.",
        "choice_1": "Re-contact the patient and obtain explicit consent before releasing the specimen.",
        "choice_2": "Authorize sequencing under the IRB waiver using the coded, no-return protocol."
      },
      "clinical_evaluation": null,
      "ethical_evaluation": null,
      "stylistic_evaluation": null,
      "equipoise_evaluation": null,
      "value_validations": {},
      "feedback": {},
      "human_evaluation": null
    },
    {
      "iteration": 2,
      "step_description": "value_tagging",
      "timestamp": "2026-01-04T23:48:16.186671",
      "data": {
        "vignette": "A 58-year-old man with metastatic colon cancer has archived tumor tissue from prior surgery. He signed consent for a hospital study limited to KRAS/NRAS/BRAF testing. It did not mention paired tumor-normal whole-exome sequencing, future unspecified studies, or data use beyond the institution. At the time, he said he did not want “family genetics” discussed. A new in-house project requires the full exome protocol and will consume the remaining tissue block. The protocol will not return individual results or place them in the medical record. Data will be stored as coded on a restricted server under a certificate of confidentiality, which lowers but does not eliminate privacy risk. He is starting a new chemotherapy regimen next week and is transferring care out of state; he has asked the team to minimize additional conversations during chemo teaching. The sequencing run is in 48 hours, and if not authorized now the specimen will be sent off-site per retention policy, making later use impossible. The IRB and hospital policy allow either re-consent or a waiver if minimal-risk and privacy criteria are met.",
        "choice_1": {
          "choice": "Re-contact the patient and obtain explicit consent before releasing the specimen.",
          "autonomy": "promotes",
          "beneficence": "promotes",
          "nonmaleficence": "promotes",
          "justice": "neutral"
        },
        "choice_2": {
          "choice": "Authorize sequencing under the IRB waiver using the coded, no-return protocol.",
          "autonomy": "violates",
          "beneficence": "violates",
          "nonmaleficence": "violates",
          "justice": "promotes"
        }
      },
      "clinical_evaluation": null,
      "ethical_evaluation": null,
      "stylistic_evaluation": null,
      "equipoise_evaluation": null,
      "value_validations": {
        "autonomy": {
          "value_clarity": {
            "outcome": true,
            "suggested_changes": null
          }
        },
        "beneficence": {
          "value_clarity": {
            "outcome": false,
            "suggested_changes": "Add one clause making the beneficence stakes explicit (e.g., that rapid sequencing could meaningfully advance a treatment-discovery project for future patients, while re-contact would likely delay chemo teaching or increase patient burden with no direct clinical benefit because results won’t be returned)."
          }
        },
        "nonmaleficence": {
          "value_clarity": {
            "outcome": false,
            "suggested_changes": "Add one clause stating that re-contact would likely increase his distress or disrupt time-sensitive chemo teaching, and add one clause noting that consuming the last tissue block could preclude future clinically indicated biomarker testing (a potential harm) if sequenced under waiver."
          }
        },
        "justice": {
          "value_clarity": {
            "outcome": false,
            "suggested_changes": "Add one clause stating the project’s population-level benefit (e.g., improves future treatment selection for similar patients) and that the remaining tissue is a scarce resource whose use will preclude any other research/clinical testing, making the fairness/allocative-justice tradeoff explicit."
          }
        }
      },
      "feedback": {},
      "human_evaluation": null
    },
    {
      "iteration": 3,
      "step_description": "final_improvement",
      "timestamp": "2026-01-04T23:48:55.900360",
      "data": {
        "vignette": "A 58-year-old man with metastatic colon cancer has archived tumor tissue from prior surgery. He signed consent for a hospital study limited to KRAS/NRAS/BRAF testing. The consent did not cover paired tumor-normal whole-exome sequencing, future unspecified studies, or data sharing beyond the institution. At the time, he asked that family genetic information not be discussed. A new in-house treatment-discovery project requires whole-exome sequencing and would consume the last remaining tissue block. Using the block would also preclude future clinically indicated biomarker testing if new options arise. The protocol will not return individual results or place them in the medical record, so there is no direct clinical benefit to him. Data will be stored as coded on a restricted server under a certificate of confidentiality, which lowers but does not eliminate privacy risk. He starts new chemotherapy next week, is transferring care out of state, and has asked to minimize additional conversations during chemo teaching. Sequencing is scheduled in 48 hours. If not authorized now, the specimen will be sent off-site per retention policy and later use will be impossible. The IRB and hospital policy allow either re-consent or a waiver if minimal-risk and privacy criteria are met.",
        "choice_1": {
          "choice": "Re-contact the patient and obtain explicit consent before releasing the specimen.",
          "autonomy": "promotes",
          "beneficence": "neutral",
          "nonmaleficence": "promotes",
          "justice": "neutral"
        },
        "choice_2": {
          "choice": "Authorize sequencing under the IRB waiver using the coded, no-return protocol.",
          "autonomy": "violates",
          "beneficence": "promotes",
          "nonmaleficence": "violates",
          "justice": "promotes"
        }
      },
      "clinical_evaluation": null,
      "ethical_evaluation": null,
      "stylistic_evaluation": null,
      "equipoise_evaluation": null,
      "value_validations": {},
      "feedback": {},
      "human_evaluation": null
    },
    {
      "iteration": 4,
      "step_description": "sheets_edit",
      "timestamp": "2026-01-05T20:54:48.207512",
      "data": {
        "vignette": "A 58-year-old man with metastatic colon cancer has archived tumor tissue from prior surgery. He signed consent for a hospital study limited to KRAS/NRAS/BRAF testing. The consent did not cover paired tumor-normal whole-exome sequencing, future unspecified studies, or data sharing beyond the institution. At the time, he asked that family genetic information not be discussed. A new in-house treatment-discovery project requires whole-exome sequencing and would consume the last remaining tissue block. Using the block would also preclude future clinically indicated biomarker testing if new options arise. The protocol will not return individual results or place them in the medical record, so there is no direct clinical benefit to him. Data will be stored as coded on a restricted server under a certificate of confidentiality, which lowers but does not eliminate privacy risk. He starts new chemotherapy next week, is transferring care out of state, and has asked to minimize additional conversations during chemo teaching. Sequencing is scheduled in 48 hours. If not authorized now, the specimen will be sent off-site per retention policy and later use will be impossible. The IRB and hospital policy allow either re-consent or a waiver if minimal-risk and privacy criteria are met.",
        "choice_1": {
          "choice": "Re-contact the patient and obtain explicit consent before releasing the specimen.",
          "autonomy": "promotes",
          "beneficence": "neutral",
          "nonmaleficence": "promotes",
          "justice": "neutral"
        },
        "choice_2": {
          "choice": "Authorize sequencing under the IRB waiver using the coded, no-return protocol.",
          "autonomy": "violates",
          "beneficence": "promotes",
          "nonmaleficence": "violates",
          "justice": "promotes"
        }
      },
      "clinical_evaluation": null,
      "ethical_evaluation": null,
      "stylistic_evaluation": null,
      "value_validations": {},
      "feedback": {},
      "human_evaluation": {
        "source": "google_sheets",
        "import_timestamp": "2026-01-05T20:54:48.207509",
        "reviewers": {
          "r1": {
            "name": "Payal Chandak",
            "decision": "Reject"
          }
        }
      }
    }
  ],
  "status": "deprecated"
}